Age: 5.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19 immunisation, Interchange of vaccine products, No adverse event, Product administered to patient of inappropriate age
Clinical narrative: 5 year old patient receive the Moderna Covid 19 Bivalent booster; 5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer.; 5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (5 year old patient receive the Moderna Covid 19 Bivalent booster), INTERCHANGE OF VACCINE PRODUCTS (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer), COVID-19 IMMUNISATION (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer) and NO ADVERSE EVENT (No adverse event) in a 5-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose 2) and PFIZER BIONTECH COVID-19 VACCINE (Dose 1). Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.    On an unknown date, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (5 year old patient receive the Moderna Covid 19 Bivalent booster), INTERCHANGE OF VACCINE PRODUCTS (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer.), COVID-19 IMMUNISATION (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (5 year old patient receive the Moderna Covid 19 Bivalent booster), INTERCHANGE OF VACCINE PRODUCTS (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer), COVID-19 IMMUNISATION (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (5 year old patient receive the Moderna Covid 19 Bivalent booster), INTERCHANGE OF VACCINE PRODUCTS (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer.) and COVID-19 IMMUNISATION (5 year old patient receive the Moderna Covid 19 Bivalent booster after receiving the primary series from Pfizer).    It was unknown if patient received other vaccines in the 4 weeks prior to COVID-19 vaccine.  No concomitant medications was reported. No treatment medications was reported.